Analysts Expect Zosano Pharma Corp (ZSAN) Will Post Earnings of -$0.24 Per Share

Equities analysts expect that Zosano Pharma Corp (NASDAQ:ZSAN) will post earnings per share of ($0.24) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Zosano Pharma’s earnings. Zosano Pharma reported earnings of ($0.46) per share during the same quarter last year, which indicates a positive year over year growth rate of 47.8%. The business is expected to announce its next quarterly earnings results on Wednesday, March 7th.

On average, analysts expect that Zosano Pharma will report full year earnings of ($0.90) per share for the current financial year. For the next year, analysts anticipate that the business will post earnings of ($0.90) per share. Zacks’ EPS calculations are an average based on a survey of research firms that cover Zosano Pharma.

Zosano Pharma (NASDAQ:ZSAN) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.05).

Separately, ValuEngine upgraded shares of Zosano Pharma from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st.

Shares of Zosano Pharma (ZSAN) traded down $0.01 during trading hours on Monday, reaching $0.57. 443,859 shares of the company were exchanged, compared to its average volume of 670,986. The stock has a market cap of $22.89, a PE ratio of -0.49 and a beta of 2.50. Zosano Pharma has a one year low of $0.50 and a one year high of $3.54.

In other Zosano Pharma news, Director Kenneth Greathouse bought 55,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The shares were bought at an average price of $0.61 per share, for a total transaction of $33,550.00. Following the transaction, the director now directly owns 200,000 shares in the company, valued at $122,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders purchased 200,000 shares of company stock worth $123,450. 2.95% of the stock is owned by corporate insiders.

An institutional investor recently raised its position in Zosano Pharma stock. Northern Trust Corp grew its stake in shares of Zosano Pharma Corp (NASDAQ:ZSAN) by 591.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,234 shares of the biotechnology company’s stock after purchasing an additional 67,774 shares during the period. Northern Trust Corp owned approximately 0.20% of Zosano Pharma worth $112,000 as of its most recent SEC filing. 19.41% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Analysts Expect Zosano Pharma Corp (ZSAN) Will Post Earnings of -$0.24 Per Share” was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/analysts-expect-zosano-pharma-corp-zsan-will-post-earnings-of-0-24-per-share/1803599.html.

Zosano Pharma Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Get a free copy of the Zacks research report on Zosano Pharma (ZSAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.